Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
RedHill Biopharma ( (RDHL) ) just unveiled an update.
On February 3, 2025, RedHill Biopharma Ltd. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, enabling the sale of American Depositary Shares (ADSs) worth up to $3,464,000. This strategic move aims to bolster RedHill’s financial flexibility and enhance its market presence, potentially impacting its operational capabilities and stakeholder interests positively.
More about RedHill Biopharma
RedHill Biopharma Ltd. is an Israeli company operating in the biopharmaceutical industry, focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases.
YTD Price Performance: -7.67%
Average Trading Volume: 16,098
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.53M
See more data about RDHL stock on TipRanks’ Stock Analysis page.
